SYK · News · 20261030N
Guidance / Outlook
STRYKER CORP · 2026-10-30 · Importance 63 · Surprise 60 · In source text
Stryker lowered its 2026 organic net sales growth outlook to 6.5%–7%. The company attributed the reduction to an unexpected slowdown in hip and knee replacement procedures, weaker-than-expected performance, and peripheral vascular supply disruptions. Management cited higher insurance premiums and deductibles as factors affecting U.S. procedure growth, and described increased pre-authorization denials as delaying patient access to treatment.
Key facts
- Stryker's new 2026 organic sales guidance was significantly reduced, while the adjusted EPS guidance cut was much smaller due to margin absorption. source
- Stryker lowered its 2026 outlook after third-quarter performance fell short of management's expectations, reflecting weaker hip and knee procedures, peripheral vascular supply disruptions and commercial execution challenges. source
- Stryker lowered its 2026 sales guidance due to an unexpected slowdown in hip and knee replacement procedures, which CEO Kevin Lobo attributed to higher insurance premiums and deductibles. source
- Stryker expected solid performance in Q4 and momentum into 2027, according to CEO Kevin A. Lobo. source
- Stryker's Q3 2026 adjusted EPS guidance fell short of consensus. source
- Stryker filed its Form 10-Q for the quarter ended September 30, 2026. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | committed | — | Stryker's new 2026 organic sales guidance was significantly reduced, while the adjusted EPS guidance cut was much smaller due to margin… |
| net_income | negative | committed | — | Stryker's new 2026 organic sales guidance was significantly reduced, while the adjusted EPS guidance cut was much smaller due to margin… |